Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuronox vs Botox in Essential Blepharospasm
NCT03216473Phase 3Completed
- Sponsor
- Medytox Inc.
- Start
- May 2016
- Primary completion
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in benign essential blepharospasm (BEB) (2 arms), sponsored by Medytox Inc. Primary endpoint: Jankovic Rating Scale sum-score at 4 weeks. Started May 2016; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT03216473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216473.